Dr. Shan Lin received his undergraduate degree from the University of California, Berkeley and completed his medical school training at Tufts University School of Medicine. He completed his ophthalmology residency and glaucoma fellowship training at the University of California, San Francisco (UCSF). He has previously been Professor of Clinical Ophthalmology at UCSF, including Director of the UCSF Glaucoma Service, and at the Zuckerberg San Francisco General Hospital. Other leadership positions include Executive Vice President of the World Glaucoma Association and Chair of the Ambassador Committee for the American Glaucoma Society.

Dr. Lin has been selected annually for 'Best Doctors' in the U.S. since 2009. He has received the American Academy of Ophthalmology's Achievement Award, Secretariat Award, and Senior Achievement Award. He is on the editorial boards for the American Journal of Ophthalmology, Journal of Glaucoma, and American Journal of Ophthalmology Case Reports. Dr. Lin has given numerous named lectures and speaks at ophthalmology meetings nationally and internationally.

Dr. Lin's areas of interest include angle-closure glaucoma, glaucoma among Asians, cyclophotocoagulation for the treatment of glaucoma, and the role of cataract surgery in glaucoma treatment. His past honors include the Heed Fellowship Award (Heed Foundation), the Mid-Career Award (American Glaucoma Society), and the Glaucoma Foundation's Clinician-Scientist Awards. He has also been funded as a Principal Investigator by the National Institutes of Health, including as the Principal Investigator at UCSF for the Ocular Hypertension Treatment Study (OHTS). In addition, Dr. Lin has been the Principal Investigator in San Francisco for many industry-sponsored clinical trials, including the Memantine Glaucoma Trial by Allergan and the Ranibizumab-Adjunctive Study for Ahmed Valve Surgery by Genentech.

Dr. Lin speaks some Mandarin Chinese.

​